Type 1 diabetes (T1D) is the most frequent form of diabetes in pediatric age, affecting more than 1.5 million people younger than age 20 years worldwide. Early and intensive control of diabetes provides continued pro-tection against both microvascular and macrovascular complications, enhances growth, and ensures normal pubertal development. In the absence of definitive reversal therapy for this disease, achieving and maintaining the recommended glycemic targets is crucial. In the last 30 years, enormous progress has been made using technology to better treat T1D. In spite of this progress, the majority of children, adolescents and young adults do not reach the recommended targets for glycemic control and assume a considerable burden each day. The development of promising new therapeutic advances, such as more physiologic insulin analogues, pioneering diabetes technology including continuous glucose monitoring and closed loop systems as well as new adjuvant drugs, anticipate a new paradigm in T1D management over the next few years. This review presents insights into current management of T1D in youths.

New therapies towards a better glycemic control in youths with type 1 diabetes / R. Cardona-Hernandez, K. Dôvc, T. Biester, L. Ekhlaspour, M. Macedoni, M. Tauschmann, C. Mameli. - In: PHARMACOLOGICAL RESEARCH. - ISSN 1096-1186. - 195:(2023 Sep), pp. 106882.1-106882.11. [10.1016/j.phrs.2023.106882]

New therapies towards a better glycemic control in youths with type 1 diabetes

M. Macedoni;C. Mameli
Ultimo
2023

Abstract

Type 1 diabetes (T1D) is the most frequent form of diabetes in pediatric age, affecting more than 1.5 million people younger than age 20 years worldwide. Early and intensive control of diabetes provides continued pro-tection against both microvascular and macrovascular complications, enhances growth, and ensures normal pubertal development. In the absence of definitive reversal therapy for this disease, achieving and maintaining the recommended glycemic targets is crucial. In the last 30 years, enormous progress has been made using technology to better treat T1D. In spite of this progress, the majority of children, adolescents and young adults do not reach the recommended targets for glycemic control and assume a considerable burden each day. The development of promising new therapeutic advances, such as more physiologic insulin analogues, pioneering diabetes technology including continuous glucose monitoring and closed loop systems as well as new adjuvant drugs, anticipate a new paradigm in T1D management over the next few years. This review presents insights into current management of T1D in youths.
Automated insulin delivery; Children; Technology; Time in range; Type 1 diabetes; Youths
Settore MED/38 - Pediatria Generale e Specialistica
set-2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
New therapies towards a better glycemic control in youths with type 1 diabetes2023.pdf

accesso aperto

Descrizione: Article
Tipologia: Publisher's version/PDF
Dimensione 698.9 kB
Formato Adobe PDF
698.9 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1009712
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact